Cargando…

Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )

To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyberg, Tommy, Harman, Katie, Zaidi, Asad, Seaman, Shaun R, Andrews, Nick, Nash, Sophie G, Charlett, Andre, Lopez Bernal, Jamie, Myers, Richard, Groves, Natalie, Gallagher, Eileen, Gharbia, Saheer, Chand, Meera, Thelwall, Simon, De Angelis, Daniela, Dabrera, Gavin, Presanis, Anne M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903446/
https://www.ncbi.nlm.nih.gov/pubmed/35184201
http://dx.doi.org/10.1093/infdis/jiac063
_version_ 1784664744555184128
author Nyberg, Tommy
Harman, Katie
Zaidi, Asad
Seaman, Shaun R
Andrews, Nick
Nash, Sophie G
Charlett, Andre
Lopez Bernal, Jamie
Myers, Richard
Groves, Natalie
Gallagher, Eileen
Gharbia, Saheer
Chand, Meera
Thelwall, Simon
De Angelis, Daniela
Dabrera, Gavin
Presanis, Anne M
author_facet Nyberg, Tommy
Harman, Katie
Zaidi, Asad
Seaman, Shaun R
Andrews, Nick
Nash, Sophie G
Charlett, Andre
Lopez Bernal, Jamie
Myers, Richard
Groves, Natalie
Gallagher, Eileen
Gharbia, Saheer
Chand, Meera
Thelwall, Simon
De Angelis, Daniela
Dabrera, Gavin
Presanis, Anne M
author_sort Nyberg, Tommy
collection PubMed
description To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI], .77–.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI, .81–.94), and COVID-19 mortality (aHR = 0.85; 95% CI, .71–1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.
format Online
Article
Text
id pubmed-8903446
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89034462022-03-09 Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( ) Nyberg, Tommy Harman, Katie Zaidi, Asad Seaman, Shaun R Andrews, Nick Nash, Sophie G Charlett, Andre Lopez Bernal, Jamie Myers, Richard Groves, Natalie Gallagher, Eileen Gharbia, Saheer Chand, Meera Thelwall, Simon De Angelis, Daniela Dabrera, Gavin Presanis, Anne M J Infect Dis Brief Report To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI], .77–.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI, .81–.94), and COVID-19 mortality (aHR = 0.85; 95% CI, .71–1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages. Oxford University Press 2022-02-20 /pmc/articles/PMC8903446/ /pubmed/35184201 http://dx.doi.org/10.1093/infdis/jiac063 Text en © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Nyberg, Tommy
Harman, Katie
Zaidi, Asad
Seaman, Shaun R
Andrews, Nick
Nash, Sophie G
Charlett, Andre
Lopez Bernal, Jamie
Myers, Richard
Groves, Natalie
Gallagher, Eileen
Gharbia, Saheer
Chand, Meera
Thelwall, Simon
De Angelis, Daniela
Dabrera, Gavin
Presanis, Anne M
Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )
title Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )
title_full Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )
title_fullStr Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )
title_full_unstemmed Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )
title_short Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )
title_sort hospitalization and mortality risk for covid-19 cases with sars-cov-2 ay.4.2 (vui-21oct-01) compared to non-ay.4.2 delta variant sublineages( )
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903446/
https://www.ncbi.nlm.nih.gov/pubmed/35184201
http://dx.doi.org/10.1093/infdis/jiac063
work_keys_str_mv AT nybergtommy hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT harmankatie hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT zaidiasad hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT seamanshaunr hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT andrewsnick hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT nashsophieg hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT charlettandre hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT lopezbernaljamie hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT myersrichard hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT grovesnatalie hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT gallaghereileen hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT gharbiasaheer hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT chandmeera hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT thelwallsimon hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT deangelisdaniela hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT dabreragavin hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages
AT presanisannem hospitalizationandmortalityriskforcovid19caseswithsarscov2ay42vui21oct01comparedtononay42deltavariantsublineages